SAB Biotherapeutics logo
SAB Biotherapeutics
SABS | NASDAQ
Chart Builder DCF Calculator
$3.00
+$0.04 (+1.35%)
At close: Nov 16, 2026, 4:00 PM ET
$3.00
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:10 PM ET

SAB Biotherapeutics Company Profile

Company profile explained

Company Profile

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Key Executives

Name Position
Samuel J. Reich CEO & Director
Christoph Bausch Executive Vice President & Chief Operating Officer
Lucy To Executive Vice President & Chief Financial Officer
Alexandra Kropotova Executive Vice President & Chief Medical Officer
Angie Parizek Senior Vice President of Clinical Operations
Carlos N. Carillo Senior Vice President of Regulatory Affairs
Catherine DeRose Vice President of Human Resources
Eddie Joe Sullivan Co-Founder, President & Director
Hua Wu Senior Vice President of Product Development
SAB Biotherapeutics
SAB Biotherapeutics logo
Country United States
IPO Date Feb 9, 2021
Industry Biotechnology
Sector Healthcare
Employees 86
CEO Samuel J. Reich

Contact Details

777 W 41st St. Miami Beach, Florida 33140 United States

Stock Details

Ticker Symbol SABS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001833214
CUSIP Number 78397T202
ISIN Number US78397T2024
SIC Code 2836

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.